Clorox Co Del Financials
Clorox Co Del (CLX) reported $7.1B in revenue for fiscal year 2025, up 0.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
With sales essentially flat, Clorox’s FY2025 rebound came from margin repair and disciplined spending rather than volume-led growth.
After its recent margin trough, revenue was basically unchanged but gross margin rebuilt from35.8% to45.2% . With SG&A also lower by FY2025, profit recovery looks driven by cost structure repair rather than a meaningfully larger sales base, so each sales dollar now leaves more room for earnings than it did at the trough.
FY2025 cash conversion was healthy: operating cash flow reached
The balance sheet remains thinly capitalized, with just
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Clorox Co Del's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Clorox Co Del, and counted as zero in the overall score.
Clorox Co Del's revenue grew a modest 0.2% year-over-year to $7.1B. This slow but positive growth earns a score of 25/100.
Clorox Co Del has elevated debt relative to equity (D/E of 7.74), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 6/100, reflecting increased financial risk.
Clorox Co Del's current ratio of 0.84 is below the typical benchmark, resulting in a score of 13/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Clorox Co Del converts 10.7% of revenue into free cash flow ($761.0M). This strong cash generation earns a score of 67/100.
Not available for Clorox Co Del, and counted as zero in the overall score.
Clorox Co Del passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Clorox Co Del generates $1.21 in operating cash flow ($981.0M OCF vs $810.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
Clorox Co Del generated $7.1B in revenue in fiscal year 2025. This represents an increase of 0.2% from the prior year.
Clorox Co Del reported $810.0M in net income in fiscal year 2025. This represents an increase of 189.3% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Clorox Co Del generated $761.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 57.6% from the prior year.
Clorox Co Del held $167.0M in cash against $2.5B in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Clorox Co Del's gross margin was 45.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 2.3 percentage points from the prior year.
Clorox Co Del's net profit margin was 11.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 7.5 percentage points from the prior year.
Clorox Co Del's ROE was 252.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 167.0 percentage points from the prior year.
Not reported for fiscal year 2025.
Capital Allocation
Clorox Co Del invested $121.0M in research and development in fiscal year 2025. This represents a decrease of 4.0% from the prior year.
Clorox Co Del spent $332.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.
Clorox Co Del invested $220.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 3.8% from the prior year.
CLX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.8B | $7.1B+0.2% | $7.1B-4.0% | $7.4B+4.0% | $7.1B-3.2% | $7.3B+9.2% | $6.7B+8.2% | $6.2B+1.5% | $6.1B+2.5% | $6.0B+3.7% | $5.8B+1.9% | $5.7B+2.6% | $5.5B-1.9% | $5.6B+2.8% | $5.5B+4.5% | $5.2B |
| Cost of Revenue | $3.8B | $3.9B-3.8% | $4.0B-9.7% | $4.5B-1.8% | $4.6B+10.1% | $4.1B+13.2% | $3.7B+4.9% | $3.5B+1.1% | $3.4B+4.5% | $3.3B+4.4% | $3.2B-0.8% | $3.2B+1.0% | $3.2B+0.5% | $3.1B+1.1% | $3.1B+5.0% | $3.0B |
| Gross Profit | $3.0B | $3.2B+5.4% | $3.0B+4.8% | $2.9B+14.3% | $2.5B-20.4% | $3.2B+4.4% | $3.1B+12.3% | $2.7B+2.0% | $2.7B+0.1% | $2.7B+2.8% | $2.6B+5.4% | $2.5B+4.6% | $2.4B-1.5% | $2.4B+5.2% | $2.3B0.0% | $2.3B |
| R&D Expenses | $116.0M | $121.0M-4.0% | $126.0M-8.7% | $138.0M+4.5% | $132.0M-11.4% | $149.0M+2.8% | $145.0M+6.6% | $136.0M+3.0% | $132.0M-2.2% | $135.0M-4.3% | $141.0M+3.7% | $136.0M+8.8% | $125.0M-3.8% | $130.0M+7.4% | $121.0M+5.2% | $115.0M |
| SG&A Expenses | $1.1B | $1.1B-3.7% | $1.2B-1.4% | $1.2B+24.0% | $954.0M-5.0% | $1.0B+3.6% | $969.0M+13.2% | $856.0M+2.3% | $837.0M+3.3% | $810.0M+0.5% | $806.0M+1.0% | $798.0M+6.3% | $751.0M-5.3% | $793.0M+1.3% | $783.0M+6.5% | $735.0M |
| Interest Expense | $97.0M | $88.0M-2.2% | $90.0M0.0% | $90.0M-15.1% | $106.0M+7.1% | $99.0M0.0% | $99.0M+2.1% | $97.0M+14.1% | $85.0M-3.4% | $88.0M0.0% | $88.0M-12.0% | $100.0M-2.9% | $103.0M-15.6% | $122.0M-2.4% | $125.0M+1.6% | $123.0M |
| Income Tax | $218.0M | $254.0M+139.6% | $106.0M+37.7% | $77.0M-43.4% | $136.0M-24.9% | $181.0M-26.4% | $246.0M+20.6% | $204.0M-11.7% | $231.0M-30.0% | $330.0M-1.5% | $335.0M+6.3% | $315.0M+3.3% | $305.0M+9.3% | $279.0M+14.8% | $243.0M-12.0% | $276.0M |
| Net Income | $756.0M | $810.0M+189.3% | $280.0M+87.9% | $149.0M-67.7% | $462.0M-34.9% | $710.0M-24.4% | $939.0M+14.5% | $820.0M-0.4% | $823.0M+17.4% | $701.0M+8.2% | $648.0M+11.7% | $580.0M+3.9% | $558.0M-2.4% | $572.0M+5.7% | $541.0M-2.9% | $557.0M |
| EPS (Diluted) | — | N/A | N/A | N/A | N/A | $5.58-24.2% | $7.36+16.5% | $6.32+1.0% | $6.26+17.0% | $5.35+8.7% | $4.92+7.7% | $4.57+4.1% | $4.39+1.9% | $4.31+6.4% | $4.05 | $2.07 |
Not reported in any period shown, so not listed: Operating Income.
TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CLX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $5.6B-3.3% | $5.8B-3.3% | $5.9B-3.5% | $6.2B-2.8% | $6.3B+1.9% | $6.2B+21.4% | $5.1B+1.1% | $5.1B+10.6% | $4.6B+1.4% | $4.5B+8.6% | $4.2B-2.3% | $4.3B-1.2% | $4.3B-1.2% | $4.4B+4.6% | $4.2B |
| Current Assets | $1.6B-0.9% | $1.6B-11.3% | $1.8B+6.0% | $1.7B-5.7% | $1.8B-9.5% | $2.0B+54.8% | $1.3B-0.5% | $1.3B-13.4% | $1.5B+2.0% | $1.5B+3.9% | $1.4B+2.4% | $1.4B-1.8% | $1.4B+3.2% | $1.4B+7.6% | $1.3B |
| Cash & Equivalents | $167.0M-17.3% | $202.0M-45.0% | $367.0M+100.5% | $183.0M-42.6% | $319.0M-63.4% | $871.0M+684.7% | $111.0M-15.3% | $131.0M-68.7% | $418.0M+4.2% | $401.0M+5.0% | $382.0M+16.1% | $329.0M+10.0% | $299.0M+12.0% | $267.0M+3.1% | $259.0M |
| Inventory | $523.0M-17.9% | $637.0M-8.5% | $696.0M-7.8% | $755.0M+0.4% | $752.0M+65.6% | $454.0M-11.3% | $512.0M+1.2% | $506.0M+10.2% | $459.0M+3.6% | $443.0M+15.1% | $385.0M-0.3% | $386.0M-2.0% | $394.0M+2.6% | $384.0M+0.5% | $382.0M |
| Accounts Receivable | N/A | N/A | N/A | N/A | $604.0M-6.8% | $648.0M+2.7% | $631.0M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $1.2B+0.1% | $1.2B-1.9% | $1.3B-19.6% | $1.6B-1.1% | $1.6B-0.1% | $1.6B-0.9% | $1.6B-0.7% | $1.6B+33.9% | $1.2B-0.1% | $1.2B+12.2% | $1.1B-3.1% | $1.1B-0.4% | $1.1B-0.6% | $1.1B+3.9% | $1.1B |
| Total Liabilities | $5.1B-3.4% | $5.3B-5.4% | $5.6B+2.4% | $5.4B-5.5% | $5.7B+8.2% | $5.3B+16.4% | $4.6B+5.1% | $4.3B+7.5% | $4.0B-4.3% | $4.2B+4.1% | $4.0B-1.4% | $4.1B-1.5% | $4.2B-7.2% | $4.5B+5.7% | $4.2B |
| Current Liabilities | $1.9B+21.9% | $1.6B-17.9% | $1.9B+7.5% | $1.8B-13.2% | $2.1B+45.0% | $1.4B-1.5% | $1.4B+20.0% | $1.2B-33.7% | $1.8B+16.1% | $1.6B+10.9% | $1.4B-14.2% | $1.6B+44.4% | $1.1B-45.0% | $2.1B+51.0% | $1.4B |
| Long-Term Debt | $2.5B+0.1% | $2.5B+0.2% | $2.5B+0.1% | $2.5B-0.4% | $2.5B-10.6% | $2.8B+21.6% | $2.3B+0.1% | $2.3B+64.2% | $1.4B-22.2% | $1.8B+0.2% | $1.8B+12.5% | $1.6B-26.5% | $2.2B+37.6% | $1.6B-26.1% | $2.1B |
| Total Equity | $321.0M-2.1% | $328.0M+49.1% | $220.0M-60.4% | $556.0M+35.3% | $411.0M-54.7% | $908.0M+62.4% | $559.0M-23.0% | $726.0M+33.9% | $542.0M+82.5% | $297.0M+151.7% | $118.0M-23.4% | $154.0M+5.5% | $146.0M+208.1% | -$135.0M-57.0% | -$86.0M |
| Retained Earnings | $432.0M+72.8% | $250.0M-57.1% | $583.0M-44.4% | $1.0B+1.2% | $1.0B-71.0% | $3.6B+13.2% | $3.1B+12.6% | $2.8B+14.6% | $2.4B+12.8% | $2.2B+12.5% | $1.9B+10.6% | $1.7B+11.4% | $1.6B+15.6% | $1.4B+18.1% | $1.1B |
CLX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $576.0M | $981.0M+41.2% | $695.0M-40.0% | $1.2B+47.3% | $786.0M-38.4% | $1.3B-17.5% | $1.5B+55.8% | $992.0M+1.6% | $976.0M+12.8% | $865.0M+11.2% | $778.0M-11.0% | $874.0M+14.0% | $767.0M-1.0% | $775.0M+26.6% | $612.0M-12.3% | $698.0M |
| Capital Expenditures | $196.0M | $220.0M+3.8% | $212.0M-7.0% | $228.0M-9.2% | $251.0M-24.2% | $331.0M+30.3% | $254.0M+23.3% | $206.0M+6.2% | $194.0M-16.0% | $231.0M+34.3% | $172.0M+37.6% | $125.0M-8.8% | $137.0M-27.9% | $190.0M+0.5% | $189.0M-17.1% | $228.0M |
| Free Cash Flow | $380.0M | $761.0M+57.6% | $483.0M-48.1% | $930.0M+73.8% | $535.0M-43.4% | $945.0M-26.9% | $1.3B+64.4% | $786.0M+0.5% | $782.0M+23.3% | $634.0M+4.6% | $606.0M-19.1% | $749.0M+18.9% | $630.0M+7.7% | $585.0M+38.3% | $423.0M-10.0% | $470.0M |
| Investing Cash Flow | -$196.0M | -$94.0M+46.3% | -$175.0M+21.5% | -$223.0M+2.6% | -$229.0M+49.3% | -$452.0M-79.4% | -$252.0M-28.6% | -$196.0M+77.2% | -$859.0M-319.0% | -$205.0M+52.3% | -$430.0M-305.7% | -$106.0M+23.2% | -$138.0M-150.9% | -$55.0M+80.1% | -$277.0M-150.9% | $544.0M |
| Financing Cash Flow | $578.0M | -$924.0M-41.1% | -$655.0M+13.0% | -$753.0M-9.3% | -$689.0M+50.5% | -$1.4B-166.0% | -$523.0M+35.8% | -$815.0M-104.3% | -$399.0M+38.1% | -$645.0M-104.1% | -$316.0M+54.6% | -$696.0M-17.6% | -$592.0M+13.6% | -$685.0M-113.4% | -$321.0M+70.2% | -$1.1B |
| Dividends Paid | $602.0M | $602.0M+1.2% | $595.0M+2.1% | $583.0M+2.1% | $571.0M+2.3% | $558.0M+4.7% | $533.0M+8.8% | $490.0M+8.9% | $450.0M+9.2% | $412.0M+3.5% | $398.0M+3.4% | $385.0M+4.6% | $368.0M+9.9% | $335.0M+6.3% | $315.0M+4.0% | $303.0M |
| Share Buybacks | $331.0M | $332.0M | $0 | $0-100.0% | $25.0M-97.2% | $905.0M+264.9% | $248.0M-62.5% | $661.0M+143.9% | $271.0M+48.1% | $183.0M-28.0% | $254.0M-41.5% | $434.0M+66.9% | $260.0M+103.1% | $128.0M-43.1% | $225.0M-65.6% | $655.0M |
TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CLX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 45.2%+2.3pp | 43.0%+3.6pp | 39.4%+3.6pp | 35.8%-7.8pp | 43.6%-2.0pp | 45.6%+1.7pp | 43.9%+0.2pp | 43.7%-1.0pp | 44.7%-0.4pp | 45.1%+1.5pp | 43.6%+0.9pp | 42.7%+0.2pp | 42.5%+1.0pp | 41.5%-1.9pp | 43.5% |
| Net Margin | 11.4%+7.5pp | 4.0%+1.9pp | 2.0%-4.5pp | 6.5%-3.2pp | 9.7%-4.3pp | 14.0%+0.8pp | 13.2%-0.2pp | 13.4%+1.7pp | 11.7%+0.5pp | 11.3%+1.0pp | 10.3%+0.1pp | 10.1%-0.1pp | 10.2%+0.3pp | 9.9%-0.8pp | 10.7% |
| Return on Equity | 252.3%+167.0pp | 85.4%+17.6pp | 67.7%-15.4pp | 83.1%-89.7pp | 172.8%+69.3pp | 103.4%-43.3pp | 146.7%+33.3pp | 113.4%-16.0pp | 129.3%-88.8pp | 218.2%-273.4pp | 491.5%+129.2pp | 362.3%-29.4pp | 391.8% | N/A | N/A |
| Return on Assets | 14.6%+9.7pp | 4.9%+2.4pp | 2.5%-5.0pp | 7.5%-3.7pp | 11.2%-3.9pp | 15.1%-0.9pp | 16.0%-0.2pp | 16.3%+0.9pp | 15.3%+1.0pp | 14.4%+0.4pp | 14.0%+0.8pp | 13.1%-0.2pp | 13.3%+0.9pp | 12.4%-1.0pp | 13.4% |
| Current Ratio | 0.84-0.2x | 1.03+0.1x | 0.950.0x | 0.97+0.1x | 0.89-0.5x | 1.42+0.5x | 0.91-0.2x | 1.09+0.3x | 0.84-0.1x | 0.95-0.1x | 1.02+0.2x | 0.85-0.4x | 1.25+0.6x | 0.67-0.3x | 0.94 |
| Debt-to-Equity | 7.74+0.2x | 7.56-3.7x | 11.26+6.8x | 4.45-1.6x | 6.04+3.0x | 3.06-1.0x | 4.09+0.9x | 3.15+0.6x | 2.57-3.5x | 6.02-9.1x | 15.14+4.8x | 10.31-4.5x | 14.80 | N/A | N/A |
| FCF Margin | 10.7%+3.9pp | 6.8%-5.8pp | 12.6%+5.1pp | 7.5%-5.3pp | 12.9%-6.3pp | 19.2%+6.6pp | 12.7%-0.1pp | 12.8%+2.2pp | 10.6%+0.1pp | 10.5%-2.7pp | 13.2%+1.8pp | 11.4%+1.0pp | 10.4%+2.7pp | 7.7%-1.2pp | 9.0% |
Not reported in any period shown, so not listed: Operating Margin.
Note: The current ratio is below 1.0 (0.84), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Clorox Co Del Ranks
Frequently Asked Questions
What is Clorox Co Del's annual revenue?
Clorox Co Del (CLX) reported $7.1B in total revenue for fiscal year 2025. This represents a 0.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Clorox Co Del's revenue growing?
Clorox Co Del (CLX) revenue grew by 0.2% year-over-year, from $7.1B to $7.1B in fiscal year 2025.
Is Clorox Co Del profitable?
Yes, Clorox Co Del (CLX) reported a net income of $810.0M in fiscal year 2025, with a net profit margin of 11.4%.
How much debt does Clorox Co Del have?
As of fiscal year 2025, Clorox Co Del (CLX) had $167.0M in cash and equivalents against $2.5B in long-term debt.
What is Clorox Co Del's gross margin?
Clorox Co Del (CLX) had a gross margin of 45.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Clorox Co Del's net profit margin?
Clorox Co Del (CLX) had a net profit margin of 11.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Clorox Co Del's return on equity (ROE)?
Clorox Co Del (CLX) has a return on equity of 252.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Clorox Co Del's free cash flow?
Clorox Co Del (CLX) generated $761.0M in free cash flow during fiscal year 2025. This represents a 57.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Clorox Co Del's operating cash flow?
Clorox Co Del (CLX) generated $981.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Clorox Co Del's total assets?
Clorox Co Del (CLX) had $5.6B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Clorox Co Del's capital expenditures?
Clorox Co Del (CLX) invested $220.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Clorox Co Del spend on research and development?
Clorox Co Del (CLX) invested $121.0M in research and development during fiscal year 2025.
What is Clorox Co Del's current ratio?
Clorox Co Del (CLX) had a current ratio of 0.84 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Clorox Co Del's debt-to-equity ratio?
Clorox Co Del (CLX) had a debt-to-equity ratio of 7.74 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Clorox Co Del's return on assets (ROA)?
Clorox Co Del (CLX) had a return on assets of 14.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Clorox Co Del's Piotroski F-Score?
Clorox Co Del (CLX) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Clorox Co Del's earnings high quality?
Clorox Co Del (CLX) has an earnings quality ratio of 1.21x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Clorox Co Del?
Clorox Co Del (CLX) scores 19 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.